MRK — Merck & Co., Inc.

NYSE · Health Care · Pharmaceuticals · CIK 310158 ·
Last close
$132.92
Market Cap
$327.94B
52W High
$135.05
52W Low
$110.15
ADV30
8,679,599
Next earnings
2026-10-29
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 16,286,000,000 12,091,000,000 -3,201,000,000 -4,240,000,000 128,685,000,000 5,327,000,000 82,754,000,000
Dec 2025 16,400,000,000 10,849,000,000 4,065,000,000 2,963,000,000 136,866,000,000 14,565,000,000 84,204,000,000
Sep 2025 17,276,000,000 13,421,000,000 6,554,000,000 5,785,000,000 129,546,000,000 18,169,000,000 77,639,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$17,890,000,000
Investing CF
$-22,464,000,000
Financing CF
$852,000,000
CapEx
$-3,775,000,000
Dividends Paid
$-8,231,000,000
Buybacks
$-4,794,000,000
EPS Diluted TTM
$1.25
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$66,721,000,000
Inventory
$6,479,000,000
Receivables
$12,210,000,000
ST Investments
$375,000,000
EBIT TTM
$13,152,000,000
Pretax Income TTM
$11,630,000,000
Interest Exp TTM
$1,522,000,000
Analysts
26

Yahoo Snapshot (yfinance, live)

Total Revenue
$66,568,998,912
EBITDA
$28,871,000,064
Free Cash Flow
$15,171,500,032
Enterprise Value
$374,757,457,920
Total Cash
$7,141,000,192
Total Debt
$53,910,999,040
Shares Out
2,467,171,638
Trailing EPS
$1.25
Book Value
$18.58
ROE
7.0%
ROA
11.9%
Div Yield
2.56%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 65,011,000,000 22,107,000,000 18,254,000,000 136,866,000,000 84,204,000,000 16,472,000,000
Dec 2024 64,168,000,000 20,221,000,000 17,117,000,000 117,106,000,000 70,734,000,000 21,468,000,000
Dec 2023 60,115,000,000 2,954,000,000 365,000,000 106,675,000,000 69,040,000,000 13,006,000,000
Dec 2022 59,283,000,000 18,282,000,000 14,519,000,000 109,160,000,000 63,102,000,000 19,095,000,000

TTM Snapshot

Revenues TTM
$53,137,000,000
NetIncome TTM
$12,566,000,000
OpCashFlow TTM
$0
Assets (Latest)
$117,106,000,000
Forward EPS
$9.55

Max Pain — expiry 2026-08-21

max pain strike: $125.00 · spot: $135.55 · call oi: 32,293 · put oi: 21,899
Expected Move to 2026-08-21: ±$4.16 (3.07%) — implied range $131.40$139.71 · ATM straddle on $136.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVSEF NOVARTIS AG $300.12B $157.90
NVS NOVARTIS AG $289.52B $152.32
AZN ASTRAZENECA PLC $245.82B $158.50
ABBV AbbVie Inc. $439.59B $248.76
ABT ABBOTT LABORATORIES $193.18B $110.91

News headlines (Yahoo Finance, 1h cache)

Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress
2026-08-13 20:07 · Yahoo
Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook
2026-08-13 19:11 · Yahoo
The Sharpest Exchanges From ABBV's Earnings Call
2026-08-13 16:10 · Yahoo
Can Keytruda Sustain Merck's Growth in the Second Half of 2026?
2026-08-13 14:00 · Yahoo
This Healthcare Services Stock Has 37% Upside
2026-08-13 12:01 · Yahoo
5 Insightful Analyst Questions From Merck’s Q2 Earnings Call
2026-08-12 23:41 · Yahoo
How ABBV Stock Moved Away From Its Peer Group
2026-08-12 20:49 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-08-12 19:58 · Yahoo
Amgen Stock And The Price Of A Promise
2026-08-12 19:17 · Yahoo
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
2026-08-12 18:36 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.